Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120

CKD progression may have an association with baseline UP/UCr and hematuria. Treatment with AST-120 may delay the time to the primary endpoint in patients with progressive CKD receiving standard therapy, thus warranting further investigation.